NASDAQ: $CKPT Introduction Checkpoint Therapeutics, a leading biopharmaceutical company, recently made a significant announcement regarding the FDA acceptance of the Biologics License Application (BLA) resubmission of Cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma. This development marks a crucial milestone in the ongoing efforts to provide effective treatment options for patients battling this…